Diagnoptics nominated for Deloitte Technology Fast50

Monday 7 September 2015

Print this page

Diagnoptics is nominated for the Deloitte Technology Fast50 Award 2015. With this nomination Diagnoptics proved to be able to show substantial growth for multiple years. The Deloitte Technology Fast50 is a yearly election of the 50 fastest growing technology companies in the Netherlands.

“Our strategy and continuous growth led to the nomination for the Deloitte Technology Fast50. This is an acknowledgement of our activities in the last few years and proves that our strategy has been successful.” said Bart van den Berg, CEO of Diagnoptics.

About Deloitte Technology Fast50

The Deloitte Technology Fast 50 is a programme that recognizes and profiles fast growing technology companies in the Netherlands. The programme ranks the 50 fastest growing public or private technology companies. Technology Fast 50 award winners for 2015 are determined based on the revenue growth over four years (2011 to 2014).

About Diagnoptics

Established in 2003, Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader - a state of art diagnostic device that can determine the tissue accumulation of AGEs in 12 seconds. Since the CE certification on the first AGE Reader in 2006, Diagnoptics has been marketing this medical device to thousands of clinics around the world. Currently the company is working on obtaining additional regulatory approvals in other regions and is engaged in new product development activities. The head office of Diagnoptics Technologies BV is in Groningen, the Netherlands.

About AGE Reader

The AGE Reader provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes, cardiovascular disease and renal failure. The AGE Reader yields a real time and non-invasive assessment of cardiovascular risk in 12 seconds. The method is convenient, easy to use and validated. The AGE Reader measures tissue accumulation of Advanced Glycation Endproducts (AGEs) by means of fluorescence techniques (skin autofluorescence). AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes, cardiovascular disease and renal failure. Since the market introduction in 2006, the AGE Reader has been clinical validated extensively in over 140 peer reviewed scientific publications.

AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The level of AGEs in tissue reflects the glycometabolic memory and is a valuable predictor of (pre)diabetes and cardiovascular complications.